Solara Active Pharma Sciences Q1 Results FY27 : Uniresearch Prediction, Analyst Views and Watchpoints

Solara Active Pharma Sciences Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue at Rs 280 Cr (-12.2% YoY) and PAT at Rs 5 Cr (-50.0% YoY), based on the Uniresearch estimate. Q4 FY26 consolidated Revenue stood at Rs 387 Cr and PAT at Rs 10 Cr per consolidated quarterly financial data. Prepared by Kunal Singla, Associate Director.

Click Here – Get Free Investment Predictions

Solara Active Pharma Sciences Q1 Results FY27: Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change
Revenue (Rs Cr)	319	280	-12.2%
PAT (Rs Cr)	11	5	-50.0%

Source: Q1 FY26 actuals from consolidated quarterly financial data. Solara Active Pharma Sciences Q1 Results FY27 prediction applies Uniresearch trailing growth rates (Revenue -12.2%, PAT -50.0%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Track Solara Active Pharma Sciences Live on Univest

Q4 FY26 Performance: Base for the Prediction

The Solara Active Pharma Sciences Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 387 Cr and PAT of Rs 10 Cr per consolidated quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 Results FY27 Uniresearch projection.

The sequential comparison also provides useful context for interpreting the Q1 Results FY27 numbers. Q4 FY26 Revenue of Rs 387 Cr reflects year-end procurement and execution cycles that may not repeat equally in the Q1 FY27. For this reason, the more meaningful benchmark for investors is the year-on-year comparison: Q1 FY27 against Q1 FY26 actual Revenue of Rs 319 Cr, where the Uniresearch estimate targets -12.2% growth. Both the YoY and sequential reads should be monitored when the actual Q1 Results FY27 numbers are declared.

Uniresearch Estimate Behind the Solara Active Pharma Sciences Q1 Results FY27 Projection

The Solara Active Pharma Sciences Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates FY27 Revenue growth of -12.2% and PAT growth of -50.0% year-on-year. Uniresearch applies these consensus growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 280 Cr Revenue and Rs 5 Cr PAT.

The Q1 FY27 estimation methodology for Solara Active Pharma Sciences is worth clarifying for investors. Uniresearch applies full-year FY27 Uniresearch estimate growth rates (-12.2% Revenue, -50.0% PAT) to Q1 FY26 verified actuals to derive the Q1 FY27 projection of Rs 280 Cr Revenue and PAT Rs 5 Cr. This approach assumes the quarterly trajectory broadly mirrors the full-year consensus direction. Intra-year seasonality and one-time events can cause actual quarterly performance to diverge from this projection. Treat this Q1 FY27 Uniresearch estimate for Solara Active Pharma Sciences as a directional benchmark, not a point forecast.

Get Expert Stock Picks on Univest

Key Watchpoints for the Solara Active Pharma Sciences Q1 Results FY27

Revenue vs Consensus Target

Whether Q1 Results FY27 Revenue delivers in line with the Rs 280 Cr Uniresearch estimate (-12.2% YoY). Q4 FY26 Revenue was Rs 387 Cr.

PAT Margin Sustainability

PAT of Rs 5 Cr (-50.0% YoY) is the Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 10 Cr. Margin stability signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond the Q1 FY27 headline numbers, Solara Active Pharma Sciences’s management commentary at the results announcement will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook from management following an in-line or beat result could support re-rating, while cautious guidance despite solid numbers may limit near-term upside. Track post-result commentary on the Univest Screener for a complete picture.

Risks to the Solara Active Pharma Sciences Q1 Results FY27 Prediction

Below-Consensus Revenue Growth

If actual Q1 Results FY27 Revenue underperforms the -12.2% growth target, the Rs 280 Cr prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges or higher costs could push PAT below Rs 5 Cr.

External and Macro Environment

The Solara Active Pharma Sciences Q1 Results FY27 performance is also exposed to macro-level risks beyond Solara Active Pharma Sciences’s direct control. Global commodity price movements, rupee-dollar exchange rate swings, domestic interest rate changes, and shifts in FII and DII sentiment toward the sector can affect input costs, realisations, and investor appetite simultaneously. A deteriorating macro environment in the Q1 FY27 could create downside risk to the Uniresearch Q1 FY27 projection even if company-specific execution remains on track.

Solara Active Pharma Sciences Q1 Results FY27: Conclusion

The Solara Active Pharma Sciences Q1 FY27 Uniresearch projection of Revenue Rs 280 Cr and PAT Rs 5 Cr is derived from Uniresearch trailing analysis. Track Solara Active Pharma Sciences live on the Univest Screener for real-time updates.

Use the Univest Screener to Track Solara Active Pharma Sciences Live

Download the Univest iOS App or Univest Android App for live Solara Active Pharma Sciences Q1 FY27 result alerts.

Frequently Asked Questions on Solara Active Pharma Sciences Q1 Results FY27

What is the Uniresearch prediction for Solara Active Pharma Sciences Q1 Results FY27?

Ans. Uniresearch projects Solara Active Pharma Sciences Q1 Results FY27 Revenue at Rs 280 Cr (-12.2% YoY) and PAT at Rs 5 Cr (-50.0% YoY), based on the Uniresearch estimate. Q1 FY26 actuals were Revenue Rs 319 Cr and PAT Rs 11 Cr.

What Uniresearch estimate is used for the Solara Active Pharma Sciences Q1 Results FY27 prediction?

Ans. The Solara Active Pharma Sciences Q1 Results FY27 prediction uses Uniresearch trailing analysis, projecting FY27 Revenue growth of -12.2% and PAT growth of -50.0% YoY. Average 12-month price target: Rs 434.

What were Q4 FY26 actuals behind the Solara Active Pharma Sciences Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 387 Cr and PAT was Rs 10 Cr per consolidated quarterly financial data.

How reliable is the Solara Active Pharma Sciences Q1 Results FY27 Uniresearch prediction?

Ans. The estimate is consensus-based, not a guaranteed outcome. Actual results may differ due to macro conditions and sector dynamics.

What base data is used for the Solara Active Pharma Sciences Q1 Results FY27 Uniresearch projection?

Ans. The Uniresearch projection for Q1 Results FY27 uses Q1 FY26 consolidated actuals (Revenue Rs 319 Cr, PAT Rs 11 Cr) as the base, sourced from Screener.in quarterly financial data. Trailing YoY growth rates (Revenue -12.2%, PAT -50.0%) are applied to these actuals to derive the Q1 Results FY27 estimate. Actuals and projections can be tracked on the Univest Screener.

What are the key risks to the Solara Active Pharma Sciences Q1 Results FY27 estimate?

Ans. Key risks: below-consensus revenue growth, margin compression, one-time provisions reducing PAT below Rs 5 Cr.

When will Solara Active Pharma Sciences declare the actual Solara Active Pharma Sciences Q1 Results FY27 data?

Ans. Solara Active Pharma Sciences will declare Q1 FY27 results after the quarter ends. Track live updates on the Univest Screener.